JHVEPhoto/iStock Editorial via Getty Images More than 99% of Catalent ( NYSE: CTLT ) shareholders who cast ballots voted in favor of the company's $16.5B acquisition by Novo Holdings. As part of the acquisition, Novo Holdings plans to sell three Catalent fill-finish sites and other assets to Novo Nordisk ( NVO ) after the merger is complete, which is expected by the end of the year.
A key reason for the acquisition is for Novo to boost its production capabilities as Catalent ( CTLT ) is a top contract development and manufacturing organization. More on Novo Nordisk, Catalent Catalent - Novo Holdings Merger: Attractive Spread Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic SA Asks: Who will launch the next big weight-loss drug?.
